A Promising Effect of Pravastatin For Reducing Preeclamsia Incidence In High Risk Pregnant Women

Zata, Fariska; Nasir, Mohammad

doi:10.33086/iimj.v1i1.1385

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of sFlt-1 decreased with increasing pravastatin dosages, particularly 2mg, 4mg, and 8mg/kg BW/day. It's in line with the theory that pravastatin has a protective impact on vascular endothelial cells and inhibits the release of sFlt-1 in the placenta as part of its pleiotropic action [14].…”

Section: Discussionsupporting

confidence: 81%

Effect of Pravastatin on Biomolecular Parameters of Preeclampsia in the Placenta of Wistar Rats

Rahardjo¹,

Jannah²,

Rahmawati³

et al. 2022

PJMHS

View full text Add to dashboard Cite

The etiology of preeclampsia consists of 2 stages, first, abnormal placentation which can increase ROS, and the inflammatory response then progresses to angiogenic imbalance. Pravastatin has a pleiotropic effect that can act as an antioxidant, anti-inflammatory, and anti-apoptotic, which is expected to be a vasodilator for angiogenic balance and reduce proinflammatory cytokines. This study aimed to examine the effect of pravastatin on the expression of angiogenic factors (sFlt-1 and VEGF) and inflammatory response (TNF-α and IL-10) in the placenta of preeclamptic rat models. This study is an experimental study, only post- test with a control group design using the placenta of preeclamptic rat models (L-NAME induced) and given pravastatin in 3 doses, namely 2 mg, 4 mg, and 8 mg.

show abstract

Section: Discussionsupporting

confidence: 81%

Effect of Pravastatin on Biomolecular Parameters of Preeclampsia in the Placenta of Wistar Rats

Rahardjo¹,

Jannah²,

Rahmawati³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…The time to reach the maximum concentration in plasma averages one hour after oral administration. 11 Statins act pleiotropic on various mechanisms: reverse angiogenic imbalance by increasing vascular endothelial growth factor (VEGF) and placental Growth Factor (PLGF), and reduce antiangiogenic factors such as soluble fmslike tyrosine Kinase-1 (sFlt-1) and soluble Endoglin (sENG). 6 Pravastatin is a competitive inhibitor of a 3 hydroxy-3-methyl-glutaryl-coenzymeAreductase which is an enzyme catalyzing step limiting levels in the synthesis of cholesterol.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Pravastatin Provision on Endotelin-1 Levels in Preeclapmsia’s High Risk Patients

Ramadhani¹,

SorayaRiu²,

Bahar³

et al. 2020

IJFMT

View full text Add to dashboard Cite

Objective: To determine the effect of pravastatin administration on endothelin-1 levels in patients at high risk of preeclampsia.Method: There are 70 subjects in this research that consist of 34 subjects with the risk of high preeclampsia who get aspirin and 36 subjects of research to get Aspirin and Pravastatin. Subjects are given therapy started the gestational age of 12-19 weeks in 6 days until 36 weeks of pregnancy. Endhotelin-1 levels prior to administration of therapy compared with the levels of endothelin-1 after the administration of treatment. Results:The test results show the administration of aspirin or aspirin and Pravastatin is shown to provide the changes were significant at levels of endothelin-1 after the administration of treatment. It is characterized by the decrease in the levels of endothelin-1 which were significantly (p <0.005). But by assessing percentage decrease in the provision of aspirin with pravastatin give change levels of endothelin-1 is large (45.74%) compared with administration of aspirin alone (28.8%). Conclusion:From this study it can be concluded that endothelin-1 levels before administration of aspirin and pravastatin were 86.18 ng/L and after administration of 46.76 ng/L. Giving aspirin and pravastatin 20 mg in patients with high risk factors of preeclampsia provide reduced levels of endothelin-1 is greater than the prevention of preeclampsia that is used when it is only aspirin.

show abstract

Evaluation of Platelet Parameters in Patients with Preeclampsia in Comparison with Healthy Pregnant Women Referring to Ganjavian Hospital in Dezful City in 2019

Mirsamiyazdi¹,

Nosratabadi²,

Masoudiyekta³

et al. 2022

Trends in Med Sci

View full text Add to dashboard Cite

Background: Preeclampsia is one of the complications of pregnancy that endangers the life of the mother and the fetus. This complication accounts for 18% of maternal mortality and is the second leading cause of maternal mortality in Iran. Various studies have shown the important role of platelets in the pathogenesis of preeclampsia. Objectives: This study was conducted to evaluate platelet parameters in patients with preeclampsia compared to healthy pregnant women who were referred to Ganjavian hospital in Dezful city in 2019. Methods: In this study, which is a retrospective case-control study, the files of women who gave birth in Ganjavian hospital in 2019 were examined. The files of the case group, which included people with preeclampsia, were selected as available samples (104 people), and the control group, which included pregnant women without preeclampsia, were randomly selected using a table of random numbers (104 cases). Criteria for entering the study in the group with preeclampsia included BP ≥ 140/90 mmHg, proteinuria of more than 300 mg in 24-hour urine or 30 mg consistently in random urine samples, and gestational age over 20 weeks. Also, people with any underlying disease, such as diabetes, chronic hypertension, known platelet disorders, multiple birth, and drug use (heparin, aspirin) in the group with preeclampsia were excluded from the study. The data of this study were analyzed using SPSS software version 20, and independent t-test, and Mann-Whitney U test at a significant level lower than 0.05. Results: There was no statistically significant difference in demographic factors between the two case and control groups. There was a statistically significant difference between the mean hemoglobin in healthy women 11.91 ± 1.30 and preeclampsia 10.89 ± 1.09 (P < 0.0001). Also, according to the findings, the individuals of the two groups had a significant difference in terms of mean platelet volume (MPV): healthy women: 10.79 ± 1.24 and preeclampsia women: 12.98 ± 1.16 (P < 0.0001). Also, the results of the Mann-Whitney U test showed that there was a statistically significant difference between the number of platelets in healthy women (284.52 ± 60.58 mm3) and preeclampsia women (149.30 ± 30.38 mm3) (P < 0.0001). Conclusions: Considering the importance of reducing the complications and mortality of pregnant mothers, early detection of changes in platelet factors during pregnancy can be a predictive factor in identifying people at risk for preeclampsia.

show abstract

A Promising Effect of Pravastatin For Reducing Preeclamsia Incidence In High Risk Pregnant Women

Cited by 3 publications

References 7 publications

Effect of Pravastatin on Biomolecular Parameters of Preeclampsia in the Placenta of Wistar Rats

Effect of Pravastatin on Biomolecular Parameters of Preeclampsia in the Placenta of Wistar Rats

The Effect of Pravastatin Provision on Endotelin-1 Levels in Preeclapmsia’s High Risk Patients

Evaluation of Platelet Parameters in Patients with Preeclampsia in Comparison with Healthy Pregnant Women Referring to Ganjavian Hospital in Dezful City in 2019

Contact Info

Product

Resources

About